Human-led · Source-checked

Biotech & Pharma Intelligence

Edition 046 · Fri 11.13.2026

A shot eased racing hearts on standing, maker says

One dose of Regeneron’s NPR1 antibody cut the heart rate jump on standing in POTS, per the company.

Read the full brief

Five things to know

  1. Must readRegeneron’s baloncibart, an NPR1-blocking antibody, slowed the heart rate rise on standing in a POTS Phase 2 One 450 mg dose cut it by 11.4 beats per minute vs placebo at day 8 in 82 adults, per Regeneron. The p-values are nominal and the effect shrank by day 29.Partial Partial NCT06593600 registers the change at day 8 and, for Cohort B only, the change in its average at day 29 as primaries; the release reports day 29 as a secondary; completed; 82 enrolled; primary c#
  2. Must readRezolute reports 13 of 16 responders in its Phase 3 of ersodetug in tumor hyperinsulinism Twelve of them stopped IV glucose, per the company. The data are preliminary, from a single-arm, open-label trial, with the full topline due by mid-December.Partial Partial NCT06881992 registers the share with a meaningful cut in IV glucose infusion at 8 weeks as the primary, 16 planned, recruiting, primary completion 09.2027; the release is a preliminary count b#
  3. Must readWindward Bio priced a $175M IPO at the midpoint with $50M from Sanofi; Vir raised $150M Both priced on a day XBI fell 3.3% and the 10-year Treasury yield rose to 5.10%. Rezera didn’t price as expected.#
  4. Know itArrowhead reports CSF tau down as much as 73% on average with ARO-MAPT, an siRNA against tau These are interim data in healthy volunteers; lower tau hasn’t yet been shown to slow disease.Partial Partial NCT07221344 registers adverse events through the end of the trial as the primary, not tau lowering; enrollment was raised to 160 from 112 on the registry; primary completion 06.2027. See 05B.#
  5. Know itVor Bio licensed a second BAFF and APRIL blocker from RemeGen for about $56M upfront RC298 is in IND-enabling work and has no human data yet; most of the upfront is paid in stock.#

Bright spot

Aravax reports that 39.4% of children on the top dose of its peptide therapy tolerated a cumulative dose of at least 443 mg of peanut protein vs 16.7% on placebo, with no treatment-related anaphylaxis, per the company. Full data are due at ACAAI on 11.14.

Verified today #

Claim Check #

Readout Registry says Headline says Verdict
Baloncibart · Regeneron PINNACLE · NCT06593600 Phase 2. Primaries: change in heart rate from lying to standing at day 8; change in its average at day 29, Cohort B only. N=82. Completed; primary completion 05.06.2026. −11.4 bpm vs placebo at day 8 (450 mg); −7.4 at day 29, reported as a secondary; the registered day 29 primary (average, Cohort B only) not reported; nominal p-values Partial
Ersodetug · Rezolute upLIFT · NCT06881992 Phase 3. Primary: share with a clinically meaningful cut in IV glucose infusion at 8 weeks. N=16 planned. Recruiting; primary completion 09.2027. 13 of 16 responders (at least a 50% cut); preliminary, 3 still in the pivotal period Partial
PVX108 · Aravax Phase 2 · NCT05621317 Phase 2. Primary: ratio of maximum tolerated peanut dose at the week 46 food challenge vs baseline, ages 4 to 11. N=95 enrolled, ages 4 to 17; the result covers 71 aged 4 to 11. Active, not recruiting; primary completion 09.26.2025. 2.4x vs 1.2x geometric mean fold change at month 12 (50 nmol) Partial
ARO-MAPT · Arrowhead Phase 1/2a · NCT07221344 Phase 1/2a. Primary: adverse events through end of trial, up to day 375. N=160 planned (was 112). Recruiting; primary completion 06.2027. CSF total tau down up to 73% on average at day 105; interim Partial

Calendar #

Date Event Who Confirmed at
2026-11-13 October PPI, 8:30 am ET BLS BLS
2026-11-14 Goal date, IGALMI (sublingual dexmedetomidine) for agitation at home, set before the sale to Teva BioXcel; Teva Company
2026-11-14 Goal date, ivonescimab with chemotherapy in EGFR-mutant non-squamous lung cancer after a third-generation EGFR TKI; Summit’s Q3 8-K (11.04) says FDA noted that a statistically significant survival benefit is necessary in this setting Summit Company
2026-11-14 Goal date, aficamten (Myqorzo) label expansion in obstructive HCM; not yet confirmed at the company Cytokinetics Aggregator
2026-11-14 ObesityWeek, National Harbor; embargo lifts 11.14 at noon ET Organizer Press
2026-11-16 POLARIS-AD Phase 3 topline of oral AR1001 in Alzheimer’s disease, at CTAD, 4:05 pm ET AriBio Company
2026-11-16 Tender offer for Pacira at $36.50 a share in cash expires one minute after 11:59 pm ET, unless extended Viatris; Pacira Company
2026-11-17 Goal date, adrabetadex (NDA); not yet confirmed at the company Beren Aggregator
2026-11-18 Senate vote on Heidi Overton’s nomination as FDA commissioner, as reported; not confirmed on a Senate page U.S. Senate Press
2026-11-22 Goal date, molgramostim inhalation solution in autoimmune pulmonary alveolar proteinosis, after a review extension Savara Company
2026-11-22 Goal date, deramiocel cell therapy in Duchenne muscular dystrophy, extended from 08.22 after a major amendment that asked FDA to consider a refined indication focused on upper limb function, per Capricor (08.24); follows a 9 to 3 advisory committee vote against approval (07.29), as reported by trade press Capricor Company
2026-11-25 Goal date, venglustat in type 3 Gaucher disease (priority review) Sanofi Company
2026-11-27 Goal date, BBP-418 in limb-girdle muscular dystrophy 2I/R9 (priority review); restated in BridgeBio’s Q3 release (10.29), which says no advisory committee is planned BridgeBio Company
2026-11-27 Goal date, neladalkib in TKI-pretreated ALK-positive lung cancer, per Nuvalent (05.27) Nuvalent Company
2026-11-27 Goal date, saroglitazar (NDA); not yet confirmed at the company Zydus Aggregator
2026-11-28 Goal date, D-PLEX100 to prevent surgical site infection in abdominal colorectal surgery (priority review) PolyPid Company
2026-11-30 Goal date, bezuclastinib with sunitinib in GIST after imatinib (priority review) Cogent Company
2026-11-30 Goal date, povetacicept in IgA nephropathy (accelerated approval), per Vertex (06.01) Vertex Company
2026-11-30 Goal date, giredestrant in ER-positive early breast cancer (priority review) Roche Company
2026-11-30 CMS deadline to publish third-cycle negotiated prices, which take effect in 2028 CMS CMS
2026-12-08 FOMC meeting; statement 12.09, 2:00 pm ET Federal Reserve Fed
2026-12-12 ASH Annual Meeting, New Orleans ASH Organizer
2026-12-12 Goal date, imsidolimab in generalized pustular psoriasis Vanda Company
2026-12-19 Goal date, imlifidase for highly sensitized patients awaiting a kidney transplant Hansa Company
2026-12-22 Goal date, lorundrostat in hypertension, reconfirmed in Q3 results (11.04) Mineralys Company
2026-12-23 Goal date, anitocabtagene autoleucel in fourth-line or later multiple myeloma, per 8-K exhibit Arcellx; Kite Company
2026-12-30 Goal date, bezuclastinib in nonadvanced systemic mastocytosis, per Cogent (03.16) Cogent Company
2027-01-21 Goal date, z-rostudirsen in Duchenne (exon 51), per Q3 results (11.05) Dyne Company
2027-02-01 New goal date, mitapivat in sickle cell disease, after a major amendment (moved from 11.01) Agios Company
2027-02-28 Goal date, QTORIN rapamycin in microcystic lymphatic malformations (priority review), per Q3 report (11.05) Palvella Company
2027-03-03 Goal date, zanzalintinib with atezolizumab in colorectal cancer, after a review extension; trade press only Exelixis Press
2027-03-10 Goal date, lonvo-z in hereditary angioedema; FDA not currently planning an advisory committee, Intellia says (Q3 results, 11.05) Intellia Company
2027-04-09 Goal date, rivoceranib with camrelizumab in unresectable liver cancer, after a third complete response letter; trade press only Elevar; Hengrui Press
2027-05-01 Goal date, AMT-130 (ifezuntirgene inilparvovec) in Huntington’s disease, BLA under priority review, seeking accelerated approval; FDA is tentatively planning an advisory committee, uniQure says uniQure Company

Registry Watch #

Trial Field Was Now
ALTITUDE-AD (Acumen sabirnetug) · NCT06335173 Primary completion 10.2026 10.29.2026
ALTITUDE-AD (Acumen sabirnetug) · NCT06335173 Completion 10.2026 12.2026
ARO-MAPT Ph1/2a · NCT07221344 Enrollment 112 160
ARO-MAPT Ph1/2a · NCT07221344 Primary outcome TEAEs through Day 315 TEAEs through end of trial, up to Day 375
COURAGE (trevogrumab) Ph2 · NCT06299098 Status Active, not recruiting Completed

Download the full briefPDF, 27 pages

Track record: our calls, graded in public · corrections log

Want this by email? Join Mind Club. It's complimentary.